Charles River Laboratories traded at $229.75 this Monday July 13th, decreasing $3.66 or 1.57 percent since the previous trading session. Looking back, over the last four weeks, Charles River Laboratories lost 21.90 percent. Over the last 12 months, its price rose by 45.37 percent. Looking ahead, we forecast Charles River Laboratories to be priced at 228.53 by the end of this quarter and at 214.50 in one year, according to Trading Economics global macro models projections and analysts expectations.
Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company provides products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions in research and drug development. The Company operates through two segments: Discovery and Safety Assessment (DSA) and Manufacturing Solutions (Manufacturing). The DSA segment includes services required to take a drug through the early development process including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (Good Laboratory Practice (GLP) and non-GLP) safety assessment services. The Manufacturing segment includes Microbial Solutions, Biologics Solutions, and Avian Vaccine Services.